EGFR exon 19 deletion

P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Jul 2025 --> Jul 2026

A 41-year-old male with metastatic lung adenocarcinoma received gefitinib as the first-line treatment. Drug binding dynamics simulation indicated reduced binding activity of osimertinib to L747_T751del and K754E mutation sites as compared to other third- or second-generation EGFR-targeted inhibitors. This study provides the first comprehensive investigation of the L747_T751del and in cis K754E mutation and its interaction with EGFR-targeted inhibitors, offering valuable clinical guidance for treating uncommon EGFR exon 19 mutations.

Drug sensitivity assays were performed to evaluate responses to Osimertinib...Unlike traditional models relying on exogenous EGFR mutations, EP cells are endogenously driven by EGFR signaling and accurately reflect the immunosuppressive microenvironment observed in patients. This model provides an efficient platform for investigating mechanisms of immune evasion and for developing innovative therapeutic strategies.

No significant differences were observed between epidermal growth factor receptor mutation subtypes. These findings are consistent with previous real-world studies and the placebo arm of the ADAURA trial, supporting the use of adjuvant osimertinib to reduce recurrence and improve long-term outcomes, while also emphasizing the need for improved perioperative risk assessment - including staging, histopathologic features, and molecular and genetic profiling - to guide personalized treatment.

In carefully selected oncology patients with highly treatment-sensitive disease, short-term VA-ECMO may be an effective bridge to systemic therapy.

This study demonstrates that EGFR-targeted therapy, when used in a first-line setting, significantly improves OS and PFS in this population. Further research is warranted to optimise treatment strategies, particularly in resource-limited settings.

P2, N=150, Active, not recruiting, Myung-Ju Ahn | Trial completion date: Jul 2025 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Mar 2026

Aumolertinib plus anlotinib was effective and well-tolerated as first-line therapy in EGFR-mutant NSCLC patients with BMs. Trial Registration: ClinicalTrials.gov(identifier NCT04978753, registered July 20, 2021).

A plasma sample serves as a supplement for identifying GPS when a tissue sample is unavailable. Moreover, the integration of FISH, NGS, and ddPCR provided a comprehensive assessment of MET amplification.

In participants with atypical EGFR-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.

Furthermore, evaluation of 7c in HCC827 (exon 19 deletion) mutation, which is a cell model highly sensitive to tyrosine kinase inhibitors, showed that the tested compound exhibited lower inhibition than erlotinib...Furthermore, 7c caused an increase in the levels of caspase 3 (4.68 folds) and caspase 9 (4.54 folds) in HCT-116 cells. Additionally, in silico studies of 7c showed a plausible binding mode that correlates with its potent inhibitory activity against the two enzymes, whereas ADME prediction revealed a favorable oral absorption.

Both almonertinib and osimertinib demonstrated good efficacy in patients with brain metastases, and PD-L1 expression was not associated with the prognosis of EGFR L858R mutant NSCLC. Finally, no significant difference between osimertinib and almonertinib for the treatment of patients with EGFR L858R mutations was observed. Both options remain viable for these patients.